May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (avastin), Treament for Exudative Macular Degeneration (amd), 6 Month Data
Author Affiliations & Notes
  • K. W. Small
    Ophthalmology, Molecular Insight LLC, Los Angeles, California
  • R. Silva
    Ophthalmology, Molecular Insight LLC, Los Angeles, California
  • Footnotes
    Commercial Relationships K.W. Small, None; R. Silva, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4571. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. W. Small, R. Silva; Intravitreal Bevacizumab (avastin), Treament for Exudative Macular Degeneration (amd), 6 Month Data. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4571.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To review our 6 month clinical experience in a private practice setting with BEVACIZUMAB (AVASTIN) in exudative AMD.

Methods:: Retrospective IRB approves review of 137 consecutive cases for 6 months. Intravitreal Avastin injections were administered every 6-8 weeks if there was evidence of an actively leaking CNVM. There were no excludion criteria.

Results:: â⑬¢ PREVIOUS TREATMENTS:33% had no previous treatment. DURATION OF WET AMD:58% > 2 years. Snellen VA change after 6 months was >+0.64 lines. Mean OCT change after 6 months was 294 microns less. P<.0001 ADVERSE EVENTS: 1 CVA (had 3 CVAs previously), 3 deaths (3 & 6 months after the injection), 2 from cancer, 1 from CHF, 1 retinal detachment.

Conclusions:: This study represents the real world since there was no exclusion criteria and many severe cases that would have been excluded from a standard prospective clinical trial.No significant safety concerns. More efficacious than MACUGEN and PDT (as monotherapy). Probably equally effective as LUCENTIS.

Keywords: age-related macular degeneration • choroid: neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×